In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?   

B-cell directed therapies with or without a standard of care (SoC) are not regarded as first-line therapies for lupus nephritis. Following the case series of successful treatments of lupus nephritis with rituximab, the LUNAR study showed that rituximab+SoC improved immunologic parameters but no...